Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors

Cancer Gene Therapy

Volumn 6, Issue 3, 1999, Pages 271-281

  Rochlitz, Christoph ^a   Jantscheff, Peter ^a   Bongartz, Georg ^a   Dietrich, Pierre Yves ^b   Quiquerez, Anne Lise ^b   Schatz, Christian ^c   Mehtali, Majid ^c   Courtney, Michael ^c   Tartour, Eric ^d   Dorval, Thierry ^d   Fridman, Wolf Herman ^d   Herrmann, Richard ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c TRANSGENE S A   (France)

^d INSTITUT CURIE   (France)

Author keywords

Cancer gene therapy; Immunotherapy; Interleukin 2; Xenogeneic cells

Indexed keywords

CD3 ANTIGEN; CYTOKINE; INTERLEUKIN 2;

ADULT; AGED; ANIMAL; ARTICLE; BIOPSY; BRAIN TUMOR; CELL CULTURE; CERCOPITHECUS; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; FEMALE; GENE THERAPY; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOGRAPHY; VERO CELL; VITILIGO;

ADULT; AGED; ANIMALS; ANTIGENS, CD3; BIOPSY; BRAIN NEOPLASMS; CERCOPITHECUS AETHIOPS; CYTOKINES; FEMALE; GENE THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; TUMOR CELLS, CULTURED; VERO CELLS; VITILIGO;

EID: 0033126594     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700047     Document Type: Article

References (33)

1. Roth C, Rochlitz CF, Kourilsky P. Immune response against tumors. Adv Immunol. 1994;57:281-351.
2. Bubenik J, Voitenok NN, Kieler J, et al. Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol Lett. 1988;19:279-282.
3. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 1989;57: 503-512.
4. Watanabe Y, Kuribayashi K, Miyatake S-I, et al. Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA. 1989;86:9456-9460.
5. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 1990;60: 397-403.
6. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990;172:1217-1224.
7. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated γ -interferon gene transfer into tumor cells generates potent and long-lasting antitumor immunity. Cancer Res. 1990;50:7820-7825.
8. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713-716.
9. + T cell-dependent tumor rejection. J Exp Med. 1991;174:1291-1298.
10. + T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med. 1992;175:1423-1431.
11. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ. Proc Natl Acad Sci USA. 1993;90:2774-2778.
12. Hock H, Dorsch M, Kunzendorf U, et al. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res. 1993;53:714-716.
13. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
14. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst. 1997;89:21-39.
15. Roth C, Mir LM, Cressent M, et al. Inhibition of tumor growth by histoincompatible cells expressing interleukin-2. Int Immunol. 1992;4:1429-1436.
16. Quintin-Colonna F, Devauchelle P, Fradelizi D, et al. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2. Gene Ther. 1996;3:1104-1112.
17. Chomczynski P, Sacchi N. Single step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
18. van-Hille B, Lohri A, Reuter J, Herrmann R. Nonradio-active quantification of mdr1 mRNA by polymerase chain reaction amplification coupled with HPLC. Clin Chem. 1995;41:1087-1093.
19. Pannetier C, Cochet M, Darche S, Casrouge A, Zöller M, Kourilsky P. The sizes of the CD3 hypervariable regions of the murine T-cell receptor β chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA. 1993;90:4319-4323.
20. Dietrich PY, Caignard A, Diu A, et al. Analysis of T cell receptor variability in transplanted patients with human cutaneous acute graft versus host disease. Blood. 1992;80: 2419-2424.
21. Dietrich PY, Caignard A, Lim A, et al. In vivo T-cell clonal amplification in human acute graft versus host disease. Blood. 1994;84:2815-2820.
22. Lüscher U, Filgueira L, Juretic A, et al. The pattern of cytokine expression in freshly excised human metastatic melanoma suggests a state of reversible anergy tumorinfiltrating lymphocytes. Int J Cancer. 1994;57:612-619.
23. Jantscheff P, Nagel G, Thompson J, et al. A CD66a-specific, activation-dependent epitope detected by recombinant human single chain fragments (scFvs) on CHO-transfectants and activated granulocytes. J Leukoc Biol. 1996;59:891-900.
24. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J Am Med Assoc. 1994;271:907-913.
25. Bubenik J, Simova J, Jandlova T. Immunotherapy of cancer using local administration of lymphoid cells expressing IL-2 cDNA and constitutively producing IL-2. Immunol Lett. 1990;23:287-292.
26. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
27. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-327.
28. Coulie PG, Somville M, Lehmann F, et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer. 1992;50:289-297.
29. Arienti F, Sule-Suso J, Belli F, et al. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther. 1996;7:1955-1963.
30. Wölfel T, Klehmann E, Müller C, Schütt K-H, Meyer zum Büschenfelde K-H, Knuth A. Lysis of human melanoma cells by autologous cytolytic T cell clones. J Exp Med. 1989;170:797-810.
31. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today. 1997;18:175-182.
32. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother. 1996;19:81-84.
33. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T-lymphocyte molecules CD28 and CTLA-4. Cell. 1992;71: 1093-1102.